HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
128,322,139
Share change
+495,786
Total reported value
$5,647,663,757
Put/Call ratio
34%
Price per share
$44.00
Number of holders
359
Value change
+$24,849,414
Number of buys
203
Number of sells
131

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2022

As of 30 Jun 2022, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 359 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 128,322,139 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, STATE STREET CORP, Invesco Ltd., WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, JPMORGAN CHASE & CO, MACQUARIE GROUP LTD, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 359 institutional shareholders reporting positions in this security for the Q2 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.